1 (8)
2 Mazer, U.S. Patent 6,251,432 B1, issued 26 June 2001
3 Mazer is prior art under 35 U.S.C. § 102(b).
4 In general, Mazer relates to a coating system for sustained release of
5 an agent from a dosage form, and particularly to a dosage form unit having a
6 latex coating for sustained release of what is characterized as a beneficial
7 agent. Col. 1, lines 6-9.
8 Apart from the principal ingredients of the dosage form, Mazer
9 indicates (col. 10, lines 35-40) (emphasis added):
10 Additional tableting aids also may be used to enhance
11 fabrication and construction of the core. For example, and as
12 embodied herein, a standard flow agent, such as talc, colloidal
13 silica, or kaolin, is included to prevent tackiness, wherein
14 fumed silica commonly available under the trademark
15 CAB-O-SIL from Cabot Corporation is preferred.
16
17 (9)
18 Sue, U.S. Patent 6,667,059 B2, issued 23 December 2003
19 Sue is prior art under 35 U.S.C. § 102(e), Sue's filing date being
20 30 May 2001.
21 Sue teaches that CAB-O-SIL is anti-tacking agent. Col. 13, Table 3.
22 Sue also teaches that talc, one of applicant's other detackifiers, is also
23 known as an anti-taking agent. Col. 13, Table 3.
24
25 Based on the new prior art references, we find that those skilled in a
26 wide variety of arts would have known that CAB-O-SILŪ could be used to
27 obviate tackiness.
12
Page: Previous 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next
Last modified: September 9, 2013